A NEW METHOD FOR ASSESSING TC-99(M)-MDP BONE UPTAKE FROM A BONE-SCAN IMAGE - QUANTITATIVE MEASUREMENT OF RADIOACTIVITY IN GLOBAL SKELETAL REGIONS OF INTEREST

被引：28

作者：

DADDABBO, A

RUBINI, G

MELE, M

LAURIERO, F

机构：

[1] Centro lnterdipartimentale di Biocibernetica e Tecniche Radioisotopiche, Cattedra di Medicina Nucleate, Università di Bari, Policlinico, Bari, Piazza Giulio Cesare

来源：

NUCLEAR MEDICINE COMMUNICATIONS | 1992年 / 13卷 / 01期

关键词：

D O I：

10.1097/00006231-199201000-00010

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Bone uptake of Tc-99m-MDP was evaluated 4 h after injection in 27 normal subjects aged 23-50 years by gamma camera measurement of the activity in whole skeleton regions of interest (ROIs) in anterior and posterior projection. The mean global skeletal uptake (GSU) (% of whole-body activity in both projections measured 30 s after injection) was 33.5 +/- 4%. The standard urinary excretion method (whole-body retention, WBR) gave a mean bone uptake value of 31.5 +/- 4%. A significant correlation (r = 0.570; P < 0.002) was found between GSU and WBR. The mean bone-to-soft tissue ratio (B/S index) was 3.0 +/- 1.1. It is suggested that this direct, external counting method provides a way of obtaining both a qualitative and a semiquantitative evaluation of bone uptake with a single tracer administration in a routine bone scan. Investigation of its use in the assessment of bone involvement in low and high turnover bone diseases is now under way.

引用

页码：55 / 60

页数：6

共 36 条

[1] Citrin D.L., Bessent R.G., McGinley E., Gordon D., Dynamic studies with<sup>99</sup>Tc<sup>m</sup>-HEDP in normal subject and in patients with bone tumors, J Nucl Med, 16, pp. 886-890, (1975)
[2] Subramanian G., McAfee J.G., Blair R.J., Kallfelz F.A., Thomas F.D., Technetium-99m-methylene diphosphonate - a superior agent for skeletal imaging: Comparison with other technetium complexes, J Nucl Med, 16, pp. 744-755, (1975)
[3] Francis M.D., Slough C.L., Tofe A.J., Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues, Calcif Tiss Res, 20, pp. 303-311, (1976)
[4] Krishnamurthy G.T., Brickman A.S., Blahd W.H., T echnetium-99m-Sn-pyrophosphate pharmaco-kinetics and bone image changes in parathyroid disease, J Nucl Med, 18, pp. 236-242, (1977)
[5] De Graaf P., Schicht I.M., Pauwels E., Te Velde J., De Graeff J., Bone scintigraphy in renal osteodystrophy, J Nucl Med, 19, pp. 1289-1296, (1978)
[6] Fogelman I., Bessent R.G., Gordon D., A critical assessment of bone scan quantitation (Bone to soft tissue ratios) in the diagnosis of metabolic bone disease, Eur J Nucl Med, 6, pp. 93-97, (1981)
[7] Mahlstedt J., Schiimichen C., Biersack H.J., Skelettszinti- graphie, Methoden Der Nuklearmedizin, (1981)
[8] Van Duzee B.F., Schaefer J.A., Ball J.D., Chilton H.M., Cowan R.J., Kuni C., Trow R., Watson NE. Relative lesion detection ability of Tc-99m HMDP and Tc-99m MDP: Concise communication, J Nucl Med, 25, pp. 166-169, (1984)
[9] De Graaf P., Pauwels E., Vos P.H., Schicht I.M., Te Velde J., De Graeff J., Observations on computerized quantitative bone scintigraphy in renal osteodystrophy, Eur J Nucl Med, 9, pp. 419-425, (1984)
[10] Galasko C., The pathophysiological basis for skeletal scintigraphy, Radionuclide Scintigraphy in Orthopaedics. Edinburgh, London, Melbourne, pp. 34-53, (1984)

← 1 2 3 4 →